TREAT OR NO TREAT - with Audio and Slides

[Guest guest]

FULL DETAILS AND LESSON LINK: http://www.mededpods.com/treatornotreat/

TREAT OR NO TREAT

Release Date: December 1, 2010 • Expiration Date: December 1, 2011 •

Estimated time to complete activity: 2.25 hours

Chronic hepatitis B (CHB) continues to be a significantly untreated disease in

the United States. Two-thirds of the estimated 1.25 million hepatitis B carriers

in the United States do not know they are infected and are unlikely to discover

their status until they show signs of potentially life-threatening illnesses.

rs of hepatitis B virus (HBV) are at increased risk for developing

cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC), with 15%

to 40% developing these serious hepatic complications in their lifetime. There

is an urgent need to screen, diagnose, and treat CHB to prevent further spread

and reduce morbidity and mortality associated with CHB.

At this case-based web posting, experts will discuss the significant advances

that have been made in the past 5 years in our understanding of the natural

history of hepatitis B and the management of patients with CHB. In addition, the

2009 American Association for the Study of Liver Diseases (AASLD) Practice

Guidelines and the most recent European Association for Study of the Liver

(EASL) Cinical Practice Guidelines will be examined. Pregnancy in the patient

with CHB also presents the provider with a unique set of management challenges

which will be addressed by the Faculty. These include maternal and fetal effects

of hepatitis B, effects of pregnancy itself on the course of hepatitis B

infection and its complications, treatment of hepatitis B during pregnancy, and

prevention of perinatal infection. In addition, patients with hepatitis B

undergoing immunosuppressive or cancer chemotherapy present a different set of

challenges for the provider, including prophylactic antiviral therapy and timing

of initiation of chemotherapy. These challenges, among others, will be addressed

in terms of the 2009 AASLD Practice Guidelines and the 2010 American Society of

Clinical Oncology Clinical Practice Guidelines.

TARGET AUDIENCE

This activity is designed for hepatologists and gastroenterologists who treat

patients with CHB.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

Integrate the 2009 AASLD Practice Guidelines into clinical practice with respect

to screening at-risk patients, treatment timing, selection of agents and

duration of treatment

Develop treatment strategies for the management of pregnant women with CHB and

for the prevention of perinatal infection in newborns

Develop management strategies for HBV carriers undergoing immunosuppressive or

cytotoxic therapy

Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF

Program Chair

Leonard Professor of Medicine

Director, Schiff Liver Institute

Director, Center for Liver Diseases

Division of Hepatology

Miami, FL

Gish, MD

Professor of Clinical Medicine

Co-director, CHAT

Chief of Clinical Hepatology

University of California

San Diego Medical Center

San Diego, CA

Mark Sulkowski, MD

Associate Professor of Medicine

Medical Director, Viral Hepatitis Center

s Hopkins University School of Medicine

Baltimore, MD

Tram T. Tran, MD

Associate Professor of Medicine

Geffen UCLA School of Medicine

Medical Director

Liver Transplant Program

Cedars-Sinai Medical Center

Los Angeles, CA